Navigation Links
Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
Date:3/24/2009

REVIEW OF RESULTS CONFIRM SAFETY AND EFFICACY FOR ROOM TEMPERATURE STORAGE

NANTONG CITY, China, March 24 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) is pleased to announce that its patented version of Cisatracurium besylate, a pre-surgical skeletal muscle relaxant marketed as Kutai in China, has successfully concluded its Phase IV Clinical Study.

The multi-center Phase IV Clinical Study investigated the safety and effectiveness of Kutai's use at room temperature. The after-market study, supported by the National Multi-center Clinical plan, was concluded successfully on September 2, 2008.

Kutai is a non-depolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action.

More than 30 clinical experts from seven participating medical centers within China gathered in Nanjing for a conference to review the results of the Phase IV of the Kutai Multi-center clinical study project.

Ms. Xinming Wu, Chief anesthetist of No.1 Hospital of Chinese Peking University Anesthesia Department, presided over the conference and delivered a summary report of the Phase IV project. Xuejun Chen, Sinobiopharma's vice president of sales was also in attendance and expressed Sinobiopharma's thanks to the participating experts for their commitment to research on Kutai.

Sinobiopharma has established a highly specialized profes
'/>"/>

SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
2. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
3. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
4. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
5. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
6. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
7. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
8. Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
9. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
10. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
11. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Antigen Discovery Inc. (ADi), a privately held ... the receipt of a National Institutes of Health (NIH) ... Institute of Dental and Craniofacial Research (NIDCR). The one-year ... Protein Microarray Chip, which will contain every protein in ... in the development of safe and effective vaccines and ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Viejo, CA (PRWEB) October 22, 2014 ... Jay Cormier, Sr. Vice President of Sales, will be ... the upcoming Meetings Technology Expo on October 28, at ... also be hosting a booth as well as a ... how Lintelus Meeting can create a more engaging event ...
(Date:10/22/2014)... News) -- Two sisters in high school have developed ... and Medha Krishen use electronic stethoscopes, which electronically amplify ... breathing patterns or heartbeats. Ilina, a senior at ... find a way to detect early lung damage in ... stethoscope, Ilina recorded one breath cycle each from 16 ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... cameraman who was diagnosed with Ebola while working for NBC ... and can leave the special isolation unit at Nebraska Medical Center ... weeks, the hospital said Tuesday. A blood test confirmed by ... Mukpo, 33, can head home to Providence, R.I., NBC News ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... World Health Organisation (WHO) has said that the risk of ... In a report analyzing 205 infections that occurred from December ... have peaked in winter and spring months, the WHO also ... this year or early next year. "If this pattern continues, ...
... World Food Programme (WFP) announced on Wednesday that as ... acute food shortage in Southern Africa. //WFP executive director ... recent years, there was a distribution problem. ... to eat," he said. "Food and good nutrition are ...
... Noel Colina, the executive director at the Institute for Occupation ... night shifts are more prone //to develop breast cancer. Citing ... said that a number of women were taking up work ... 6 a.m. ,This type of work usually done ...
... A protein that allows breast cancer cells to evade the body’s ... according to a study by Keck School of Medicine of USC ... issue of the American Journal of Pathology, is the first to ... of cells – functions. ,“The important aspect of ...
... Glucosamine, a substance used in treating arthritis was now found ... UV damaged skin and preventing the //formation of new age ... Harvard Medical School have reported that the more stable n-acetyl ... cells thus proved its effect in UV-related skin damage treatment. ...
... Shire was the foremost patch medication approved to treat ... of methylphenidate - DAYTRANA, is now available in pharmacies ... 20 mg and 30 mg. ,'The availability of DAYTRANA, ... and parents with a new, practical way to individualize ...
Cached Medicine News:Health News:Researchers Investigate Protein that Protects Tumors 2Health News:Study Finds - UV Damaged Skin could be Possibly Treated with Glucosamine 2Health News:Study Finds - UV Damaged Skin could be Possibly Treated with Glucosamine 3Health News:Shire Developed DAYTRANA – The First Medication to Treat ADHD Symptom 2Health News:Shire Developed DAYTRANA – The First Medication to Treat ADHD Symptom 3Health News:Shire Developed DAYTRANA – The First Medication to Treat ADHD Symptom 4
McPherson titanium tying forceps which is 5 mm long, smooth jaws and straight. Used for 8-0 to 11-0 sutures....
Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches....
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Medicine Products: